Genzyme to buy Bone Care, widen Hectorol approval

05/5/2005 | MarketWatch

Genzyme said it plans to buy Bone Care International, make it part of Genzyme's U.S. renal operations and take advantage of the firm's $119 million cash on hand. Genzyme said it plans to register Bone Care's Hectorol, for treating secondary hyperparathyroidism associated with kidney dialysis, in other countries after it completes the estimated $600 million acquisition.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX